Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 6/20 | 0.37 |
| ▸ | FEN1 | P39748 | 6/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.36 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7105798 | 0.92 | POLB (0.37) | RXFP1POLBFNTAFNTBTLR8 | |
| SCHEMBL6178561 | 0.85 | KCNA5 (0.36) | FNTAFNTBALOX5APFEN1KCNA5 | |
| SCHEMBL6163480 | 0.84 | POLB (0.44) | RXFP1POLBFNTAFNTBTLR8 | |
| SCHEMBL7105111 | 0.83 | F2RL3 (0.45) | RXFP1POLBFNTAFNTBTLR8 | |
| SCHEMBL7103244 | 0.82 | CYP19A1 (0.44) | RXFP1POLBFNTAFNTBTLR8 | |
| SCHEMBL7107442 | 0.81 | AGTR2 (0.37) | RXFP1POLBTLR8TLR7P2RY12 | |
| SCHEMBL7102321 | 0.81 | POLB (0.43) | RXFP1POLBFNTAFNTBELANE | |
| SCHEMBL6468248 | 0.81 | F10 (0.43) | ALOX5APFEN1KCNA5F10MMP3 | |
| SCHEMBL7100618 | 0.80 | POLB (0.44) | RXFP1POLBFNTAFNTBTLR8 | |
| SCHEMBL6238920 | 0.79 | MAPK14 (0.47) | RXFP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030065176-A1 | Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof | LG CHEM INVESTMENT LTD. (KR) | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065176-A1 | Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof | F2, F12, TFPI | RXFP1 1251/4885POLB 3482/4885FNTA 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.